Galapagos NV (NASDAQ:GLPG) Shares Bought by Headlands Technologies LLC

Headlands Technologies LLC raised its holdings in Galapagos NV (NASDAQ:GLPG) by 56.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,233 shares of the biotechnology company’s stock after purchasing an additional 446 shares during the period. Headlands Technologies LLC’s holdings in Galapagos were worth $31,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Quadrant Capital Group LLC raised its position in shares of Galapagos by 18.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 261 shares in the last quarter. Barometer Capital Management Inc. acquired a new stake in shares of Galapagos during the 4th quarter valued at approximately $122,000. China Universal Asset Management Co. Ltd. raised its position in shares of Galapagos by 66.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 3,769 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 1,504 shares in the last quarter. Signaturefd LLC raised its position in shares of Galapagos by 48.1% during the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 1,258 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Galapagos by 21.6% during the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 814 shares in the last quarter. 32.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on GLPG. Leerink Partnrs raised Galapagos to a “hold” rating in a research report on Monday, September 9th. Leerink Partners assumed coverage on Galapagos in a research report on Monday, September 9th. They set a “market perform” rating and a $24.00 price target on the stock. Finally, Raymond James downgraded Galapagos from an “outperform” rating to a “market perform” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the stock. According to MarketBeat, Galapagos has a consensus rating of “Hold” and a consensus target price of $31.00.

Galapagos Stock Performance

Shares of GLPG opened at $30.56 on Wednesday. The stock has a fifty day moving average price of $27.01 and a 200 day moving average price of $28.53. Galapagos NV has a 12 month low of $24.16 and a 12 month high of $42.46.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.